GHK-Cu Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion

What GHK-Cu Is and Why Its Pharmacokinetics Matter

GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a tripeptide first isolated from human plasma in 1973 by Loren Pickart. It binds a single copper(II) ion with extraordinarily high affinity (Kd ~10⁻¹⁶ M) and functions as a signaling molecule for wound repair, collagen remodeling, and anti-inflammatory gene regulation 1.

Understanding its ADME profile matters for two reasons. First, clinicians prescribing subcutaneous GHK-Cu from 503A compounding pharmacies need to know how quickly it reaches target tissues and how long its biological signal persists. Second, topical formulations require evidence that the intact tripeptide-copper complex actually crosses the stratum corneum. Without a formal FDA pharmacokinetic dossier, the ADME picture must be assembled from peptide chemistry principles, in-vitro permeation data, and the limited in-vivo work published in peer-reviewed literature 2.

Plasma concentrations of endogenous GHK-Cu decline with age. Pickart's original work measured approximately 200 ng/mL in healthy 20-year-olds, falling to roughly 80 ng/mL by the sixth decade 1. That 60% drop correlates with reduced wound-healing capacity and diminished collagen turnover, which partly explains the clinical interest in exogenous supplementation.

Absorption: Subcutaneous vs. Topical Routes

Subcutaneous injection produces the most predictable absorption profile. GHK-Cu's molecular weight of 403.9 Da and high aqueous solubility allow rapid diffusion from the injection depot into dermal capillaries. Peak plasma concentrations are estimated within 15 to 30 minutes, consistent with other small peptides like BPC-157 and thymosin beta-4 that share comparable molecular weights 3.

No formal bioavailability study with radiolabeled GHK-Cu has been published. However, the peptide's physicochemical profile (low molecular weight, moderate hydrophilicity, no disulfide bonds) suggests subcutaneous bioavailability in the 80 to 95% range, comparable to insulin analogs and other small-peptide injectables described in the literature on subcutaneous drug delivery 4.

Topical absorption is more complex. The "500 Dalton rule" in dermatology holds that molecules below 500 Da can cross the stratum corneum, and GHK-Cu sits just under that threshold 5. Permeation studies using copper peptide-loaded liposomes and iontophoresis-enhanced delivery systems have demonstrated measurable dermal concentrations in ex-vivo human skin models. A 2015 study by Badenhorst and colleagues confirmed that copper peptide complexes can permeate porcine skin when formulated in appropriate vehicles 2.

The intact GHK-Cu complex likely dissociates and reassociates as it moves through skin layers. Copper(II) can be chelated by competing histidine residues in dermal proteins, meaning a fraction of the applied dose may deliver "free" GHK tripeptide and ionic copper separately rather than as the intact complex. Vehicle formulation (cream, serum, liposome) significantly influences how much reaches the papillary dermis.

Distribution: Where GHK-Cu and Its Copper Travel

Once absorbed, GHK-Cu distributes preferentially to copper-avid tissues. The peptide circulates bound to its copper ion, but rapid exchange occurs with serum albumin, which carries approximately 75% of exchangeable copper in plasma 6. This albumin-mediated shuttling delivers copper to the liver, where ceruloplasmin incorporates it for systemic distribution.

Tissue-level evidence supports accumulation in skin, liver, bone marrow, and sites of active inflammation. This is expected. GHK-Cu upregulates genes involved in extracellular matrix remodeling, and tissues with high collagen turnover show the greatest response. A gene-expression analysis by Campbell and colleagues found that GHK-Cu modulates 4,048 human genes at a concentration of 1 µM, with pronounced effects on genes governing TGF-beta superfamily signaling and connective tissue growth factor 7.

The volume of distribution has not been formally calculated. For a hydrophilic tripeptide of this size, a volume of distribution approximating extracellular fluid (0.2 to 0.3 L/kg) is a reasonable pharmacokinetic estimate, though this remains unconfirmed by clinical measurement. Protein binding is dominated by the albumin interaction, with the copper ion itself showing high affinity for histidine-containing plasma proteins.

Mechanism of Action: How GHK-Cu Signals at the Molecular Level

GHK-Cu does not fit neatly into the receptor-agonist model used for most drugs. Instead, it functions through at least three overlapping pathways that explain its broad tissue-repair activity.

The first pathway involves copper delivery to lysyl oxidase, the enzyme responsible for cross-linking collagen and elastin fibers. Without adequate copper, lysyl oxidase activity falls and connective tissue loses structural integrity. GHK-Cu provides bioavailable copper directly to this enzyme system, supporting collagen types I and III synthesis in fibroblasts 1.

The second pathway operates through gene expression. The 2012 Broad Institute Connectivity Map analysis demonstrated that GHK-Cu at 1 µM concentration resets gene expression patterns associated with tissue destruction. Specifically, it suppresses genes encoding metalloproteinases (MMP-2, MMP-9) and pro-inflammatory cytokines (IL-6, TNF-alpha) while upregulating genes for antioxidant enzymes including superoxide dismutase and glutathione S-transferases 7.

The third pathway centers on fibrinogen binding. GHK-Cu binds to the high-affinity site on fibrinogen (Kd approximately 1.0 × 10⁻⁹ M), and this interaction triggers chemoattraction of monocytes and macrophages to wound sites 8. The result is a coordinated repair response: inflammatory cells arrive, debris is cleared, and fibroblasts receive copper and signaling cues simultaneously.

These three mechanisms operate in parallel. A single dose of GHK-Cu simultaneously provides the raw material for collagen cross-linking, reprograms the local gene-expression environment, and recruits immune cells to the repair site. This multi-target pharmacology explains why the peptide shows activity in wound healing, hair growth, bone repair, and skin remodeling despite being a simple tripeptide 1.

Metabolism: Peptidase Hydrolysis and Copper Recycling

GHK-Cu follows the metabolic fate of all small, unprotected peptides. Plasma aminopeptidases and carboxypeptidases cleave the glycine-histidine and histidine-lysine bonds within minutes of systemic exposure. The estimated plasma half-life of 0.5 to 1 hour reflects this rapid enzymatic degradation 1.

The resulting amino acids (glycine, histidine, lysine) enter normal amino acid pools. None are unusual or toxic. The released copper(II) ion immediately binds to albumin (forming the copper-albumin complex that constitutes the exchangeable copper pool) and is subsequently incorporated into ceruloplasmin by hepatocytes 6.

One pharmacologically relevant point: the biological signal from GHK-Cu may persist longer than the intact peptide. Gene-expression changes triggered by the 1 µM concentration pulse take hours to manifest fully and may endure for 24 to 48 hours after the peptide itself has been hydrolyzed. Dr. Loren Pickart noted in his 2018 review that "the actions of GHK on gene expression are more long-lasting than would be predicted from the peptide's short plasma half-life" 1.

This disconnect between pharmacokinetic half-life and pharmacodynamic duration is common among signaling peptides. It is one reason why daily dosing (rather than continuous infusion) appears sufficient for clinical effect.

No cytochrome P450 enzymes are involved in GHK-Cu metabolism. The peptide does not interact with CYP3A4, CYP2D6, or other hepatic drug-metabolizing enzymes, which makes drug-drug interactions through metabolic competition extremely unlikely 9.

Excretion: Renal Clearance of Fragments

The hydrolysis products of GHK-Cu (glycine, histidine, lysine) follow standard amino acid excretion pathways. Free amino acids are filtered at the glomerulus and reabsorbed in the proximal tubule with greater than 98% efficiency under normal renal function. Only trace quantities appear in urine 10.

Copper excretion occurs primarily through biliary secretion. The liver packages excess copper into bile via the ATP7B transporter (the same transporter mutated in Wilson disease). Under normal copper homeostasis, biliary copper excretion accounts for approximately 2 mg per day, while urinary copper loss is minimal at 30 to 60 µg per day 11.

A single 1 to 3 mg subcutaneous dose of GHK-Cu delivers approximately 0.16 to 0.48 mg of elemental copper. This is well within the normal daily copper intake range of 0.9 to 2.0 mg from diet alone, meaning exogenous GHK-Cu does not meaningfully perturb total body copper balance in patients without pre-existing copper metabolism disorders 11.

Total body clearance of the intact peptide has not been measured directly. Based on its rapid hydrolysis and the amino acid profiles of its fragments, renal clearance of intact GHK-Cu is presumed negligible because the peptide is degraded before meaningful glomerular filtration can occur.

Clinical Pharmacokinetic Gaps and What They Mean for Prescribers

The single largest gap in GHK-Cu pharmacokinetics is the absence of formal human PK studies with serial plasma sampling, AUC calculations, and mass-balance data. This absence exists because GHK-Cu is used under the 503A compounding framework and has never been submitted to the FDA as a new drug application 12.

Several practical consequences follow from this gap. Dose-response relationships remain empirical rather than pharmacokinetically derived. The commonly used subcutaneous dose range of 1 to 3 mg daily comes from clinical observation and tolerability rather than from Cmax/AUC optimization. Topical concentrations, typically 1 to 4% in compounded creams, are based on in-vitro efficacy data rather than formal dermal PK studies.

The Endocrine Society and the American Academy of Dermatology have not issued formal dosing guidelines for GHK-Cu. Clinicians prescribing it rely on the peptide therapy literature, clinical experience from compounding pharmacy networks, and the safety data summarized in Pickart's 2018 comprehensive review 1.

For patients with Wilson disease, hemochromatosis, or other copper metabolism disorders, the copper content of GHK-Cu requires specific clinical consideration. The 0.16 mg of copper per milligram of GHK-Cu is a measurable load for individuals who cannot properly excrete or regulate copper 11.

How GHK-Cu Compares to Other Peptide Therapeutics in PK Profile

GHK-Cu's pharmacokinetic profile is typical of unmodified small peptides. Its half-life of 0.5 to 1 hour places it in the same category as BPC-157 (estimated half-life of roughly 4 hours based on animal models) and well below PEGylated or acylated peptides like semaglutide, whose half-life reaches approximately 168 hours due to albumin-binding fatty acid side chains 13.

This comparison is instructive. The short half-life means GHK-Cu requires daily administration, while semaglutide needs only weekly dosing. Researchers have explored modifications to extend GHK-Cu's half-life, including PEGylation and encapsulation in slow-release nanoparticles. A 2020 study demonstrated that GHK-Cu loaded into PLGA nanoparticles achieved sustained release over 72 hours in vitro 3. These extended-release formulations are not yet commercially available through compounding pharmacies.

The Connectivity Map analysis of GHK-Cu gene-expression changes suggests that the peptide's brief systemic presence triggers durable downstream effects, somewhat analogous to how a short-acting kinase inhibitor can produce prolonged pathway suppression 7. This pharmacodynamic persistence partially compensates for the short pharmacokinetic half-life and supports the once-daily dosing regimen used in current clinical practice.

Patients switching from or combining GHK-Cu with other peptide therapies should note the absence of CYP450-mediated interactions, which simplifies co-administration from a metabolic standpoint 9. The primary concern with combination peptide regimens is additive copper load if multiple copper-containing compounds are used simultaneously.